GlassScriptPhysician profile
Brooke T Wiggins
NPI 1962116483
$580.50
in general payments reported to CMS, 2019-2025
14 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $73.83 | 2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $72.47 | 2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $66.53 | 2025 | Rexulti |
| Novo Nordisk INC | $56.98 | 2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $56.38 | 2025 | |
| Novartis Pharmaceuticals Corporation | $56.00 | 2025 | |
| Pfizer INC. | $49.60 | 2025 | |
| Glaxosmithkline, LLC. | $41.88 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.23 | 2025 | Xifaxan |
| Ardelyx, INC. | $18.84 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $18.00 | 2025 | Airsupra |
| Merck Sharp & Dohme LLC | $17.77 | 2025 | Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2025 | Jardiance |
| Exact Sciences Corporation | $13.56 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.